Contact

Steady Lantern 69 Home About Services Mechanisms & Effects Evidence & Risk Access & Legal Status Contact Evidence, context & careful comparison Psilocybin Vs Ibogaine: Your Questions Answered Both substances are receiving attention as psychedelic compounds, yet their mechanisms, research bases, therapeutic settings, and safety concerns are meaningfully different. For adults seeking a grounded comparison of evolving research, risk, and access. A careful starting point Understanding the comparison Psilocybin and ibogaine are psychoactive compounds with very different histories and present-day research paths. Psilocybin is the psychoactive ingredient in certain mushrooms and is generally discussed in medicine as a standardized drug used with psychological support. Ibogaine is an alkaloid from the iboga plant, whose Gabonese origin connects it to spiritual traditions and traditional use in West Central Africa. When considering psilocybin and ibogaine, it is important to separate early therapeutic potential from established care. Both can lead to intense psychedelic experiences, but neither is a simple or risk-free answer for mental health conditions, addiction, or personal growth. For background on the plant itself, a description of Tabernanthe iboga and its botanical context helps clarify why ibogaine is often described as plant medicine rather than as a conventional medication. Meaningful differences matter most when the conversation includes evidence, medical screening, legal context, and support after the experience. Psilocybin Understanding psilocybin How psilocybin works in the brain Psilocybin is metabolized in the body to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, particularly in the prefrontal cortex. This mechanism of action can alter brain activity, perception, emotion, and a person’s sense of self during an experience. Research suggests that changes involving serotonin receptors may support neuroplasticity: the b

Contact

A considered place for feedback.